Please assess the completion status of the following clinical trial:

Trial Title: Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Eligible participants must have multiple myeloma using standard criteria.~2. Patients must have measurable disease requiring systemic therapy defined as at least one of the following:~   * Serum M-protein ≥1 g/dl (≥10 g/l)~  * Urine M-protein ≥200 mg/24 hrs~  * Serum free light chain assay: involved free light chain level ≥10 mg/dl (≥100 mg/l) provided the serum free light chain ratio is abnormal~3. Must have progressed during or after at least one previous bortezomib-containing treatment regimen. Patients who have received previous high-dose therapy/autologous stem cell transplantation are eligible.~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.~5. Must meet the following laboratory criteria:~   * Absolute neutrophil count (ANC) ≥1000/μL;~  * Platelets ≥70,000/microL;~  * AST or ALT and alkaline phosphatase (ALP) must be ≤ 2.5 x ULN, or ≤ 5 x ULN in patients with plasmacytomas of the liver;~  * Total bilirubin ≤ 1.5 x the institutional ULN;~  * Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml/min;~  * Serum potassium, calcium, magnesium WNL (These may be corrected prior to starting therapy, to make the patient eligible.)~6. Ability to swallow oral medications.~7. Baseline MUGA or ECHO must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional limits of normal.~8. Male or females ≥ 18 years of age.~9. Female patients must not be of child-bearing potential or must agree to use adequate contraceptive measures.~10. Male patients willing to use adequate contraceptive measures.~11. Willingness and ability to comply with the trial and follow-up procedures.~12. Ability to understand the nature of this trial and give written informed consent.~Exclusion Criteria:~1. Currently receiving or have received systemic cancer therapy (chemotherapy, biologic therapy) ≤ 21 days of initiating study therapy. For patients receiving small molecule targeted therapy, study treatment may begin \>21 days after last dose or \>5 half lives of previous treatment, whichever is shorter. Patients must have completed radiation therapy ≥7 days prior to starting study treatment. Patients must have recovered from or come to a new chronic stable baseline from all treatment-related toxicities. Dexamethasone or other high-dose steroid therapy must be stopped ≥ days prior to starting study treatment.~2. Previous treatment with HDAC, DAC, HSP90 or valproic acid for treatment of cancer.~3. Requires valproic acid for any medical condition during the study ≤5 days prior to first panobinostat treatment.~4. Patient has not recovered from all therapy-related toxicities associated with prior treatments to \< Grade 2 CTCAE.~5. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).~6. Patients with pleural effusions requiring thoracentesis or ascites requiring paracentesis ≤14 days prior to study entry.~7. Patients using medications that have a risk of prolonging the QT interval or inducing Torsade de Pointes if treatment cannot be discontinued or switched to a different medication prior to receiving study drug.~8. Patients with \> grade 2 diarrhea.~9. Patients with impaired cardiac function.~10. Infection requiring IV antibiotics.~11. Patients with \> grade 2 peripheral neuropathy or with uncontrolled pain.~12. Women who are pregnant or lactating.~13. Any concurrent medical illness that may impair the ability of the patient to tolerate study treatment and comply with the requirements of the study.~14. Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.~15. Use of any non-approved or investigational agent ≤30 days prior to administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.~16. Presence of other active cancers, or history of treatment for invasive cancer ≤ 5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Carfilzomib and Panobinostat (Type: EXPERIMENTAL): Phase I:~Carfilzomib: cycle 1 - Dose is 20 mg/m\^2 IV on day 1; 27 or 36 or 45 or 56 mg/m\^2 IV on Days 8, 9, 15, 16 cycle 2 to progression - 27 or 36 or 45 or 56 mg/m\^2 IV on days 1, 2, 8, 9, 15, 16~Panobinostat: cycle 1 and cycle 2 to progression - 20 mg or 30 mg on days 1, 3, 5, 15, 17, 19~Phase II:~Carfilzomib and Panobinostat: Dose is optimal dose determined in Phase I

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete